Liposarcoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 30: | Line 30: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Trabectidin | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Trabectidin | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Trabectidin 1.5mg/m2 21 day cycle | | style="padding: 5px 5px; background: #F5F5F5;" |Trabectidin 1.5mg/m2 21 day cycle<ref name=AO>{{cite web | title = Liposarcoma | url = http://annonc.oxfordjournals.org/content/23/6/1601/T2.expansion.html }}</ref> | ||
|} | |} | ||
Revision as of 19:24, 19 September 2014
|
Liposarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Liposarcoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Liposarcoma medical therapy |
|
Risk calculators and risk factors for Liposarcoma medical therapy |
| Drugs | Dose |
|---|---|
| Doxurubicin | Doxurubicin 75 mg/m2; 28 day cycle |
| Pegylated liposomal doxurubicin | 40-50 mg/m2 ; 28 day cycle |
| AI regimen | Doxurubicin 25 mg/m2, Ifosfamide 3g/m2 21 day cycle |
| MAID regimen | Doxurubicin 20 mg/m2, ifosfamide 2.5g/m2, Dacarbazine 300mg/m2 21 day cycle |
| AD regimen | Doxurubicin 20 mg/m2, Dacarbazine 300mg/m2; 21 day cycle |
| Metronomic cyclophosphamide | Oral daily cyclophosphamide 50mg/day for 21 dyas on 28 day cycle |
| Docetaxel-Gemcitabine | Gemcitabine 900 mg/m2 , Docetaxel 100 mg/m2 for 21 day cycle |
| Trabectidin | Trabectidin 1.5mg/m2 21 day cycle[1] |